Nyxoah SA Stock News

Nyxoah Provides an Update on Expanded Middle East Presence New Centers in Dubai, Kuwait, and Abu Dhabi Following First Genio® Implant in the Region Earlier in 2025 Mont-Saint-Guibert, Belgium – September 23, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA),...

Nyxoah Files Patent Infringement Lawsuit Against Inspire Medical Systems, Inc. Mont-Saint-Guibert, Belgium – September 15, 2025, 10:10pm CET / 4:10pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) and Nyxoah, Inc. (collectively, “Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that it h...

Nyxoah SA. / BE0974358906

Nyxoah SA. / BE0974358906

Nyxoah SA (NASDAQ:NYXH ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 5:35 PM EDT Company Participants Olivier Taelman - CEO & Executive Director Presentation Unknown Analyst Excellent. Thank you, everyone, for joining us.

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 5, 2025 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. On September 4, 2025, Nyxoah rec...

Nyxoah Announces Upcoming Investor Events Mont-Saint-Guibert, Belgium – September 2, 2025, 10:30pm CET / 4:30PM ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the following events during September: 20...

Nyxoah's Genio system received FDA approval, unlocking access to the US market and validating its innovative, patient-friendly OSA treatment. Recent earnings show strong revenue growth but continued losses as Nyxoah invests heavily in US commercialization and expansion efforts. Key risks include rising debt, dilution, ongoing patent litigation, and high competition, but GLP-1 drugs pose less th...